Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, V.le Bracci, 16, 53100, Siena, Italy.
Italian Network for Tumor Bio-Immunotherapy Foundation, Center for Immuno-Oncology, Istituto Toscano Tumori, University Hospital of Siena, 53100, Siena, Italy.
Cancer Immunol Immunother. 2019 Jan;68(1):1-9. doi: 10.1007/s00262-018-2285-y. Epub 2018 Dec 18.
A collaborative think tank involving panellists from immuno-oncology networks, clinical/translational investigators and the pharmaceutical industry was held in Siena, Italy, in October 2017 to discuss the evolving immune-oncology landscape, identify selected key challenges, and provide a perspective on the next steps required in the translation of current research and knowledge to clinical reality. While there is a trend of combining new agents (e.g., co-stimulator agonists) with a PD-1/PD-L1 treatment backbone, use of alternative combination therapy approaches should also be considered. While the rapid evolution in systems biology provides a deeper understanding of tumor and tumor microenvironment heterogeneity, there remains the need to identify and define genuinely predictive biomarkers to guide treatment and patient selection. Cross-specialty and cross-sector collaboration, along with a broader collective data-sharing approach are key to optimizing immuno-oncology therapy in clinical practice. Continued support of younger research-clinicians is essential for future success in clinical, translational and basic science investigations.
一个由免疫肿瘤学网络、临床/转化研究人员和制药行业的专家组成的合作智囊团于 2017 年 10 月在意大利锡耶纳举行，讨论不断发展的免疫肿瘤学领域，确定选定的关键挑战，并就将当前研究和知识转化为临床现实所需的下一步提供看法。虽然有将新型药物（如共刺激激动剂）与 PD-1/PD-L1 治疗骨干联合使用的趋势，但也应考虑使用替代联合治疗方法。尽管系统生物学的快速发展提供了对肿瘤和肿瘤微环境异质性的更深入了解，但仍需要确定和定义真正具有预测性的生物标志物，以指导治疗和患者选择。跨专业和跨部门的合作，以及更广泛的集体数据共享方法，是优化免疫肿瘤学治疗在临床实践中的关键。继续支持年轻的研究临床医生对于未来在临床、转化和基础科学研究中的成功至关重要。
